SCHEMBL29319429

SCHEMBL29319429

COc1ccc(COc2c(F)cc(C(=O)NC[C@]34CC[C@](c5nc(-c6ccnc(N7CCN(C(=O)OC(C)(C)C)CC7)n6)cs5)(CC3)CC4)c(F)c2F)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TLR9 Q9NR96 2/20 0.37
GPR119 Q8TDV5 7/20 0.36
SLC2A1 P11166 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TP53 P04637 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
TBK1 Q9UHD2 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33
GALR2 O43603 1/20 0.33
GALR1 P47211 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30995409 1.00 ACHE (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL30995379 0.87 GPR119 (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL29319793 0.87 GPR119 (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL30995287 0.87 TLR9 (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL29318390 0.87 TLR9 (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL27213776 0.87 TLR9 (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL30995325 0.83 TLR9 (0.37) ACHELMNAMAPTSMN1; SMN2TLR9
SCHEMBL30995403 0.83 SLC6A9 (0.32)
SCHEMBL29319434 0.83 SLC6A9 (0.32)
SCHEMBL30995334 0.83 CSF1R (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 ACHE 4139/4885LMNA 1598/4885MAPT 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.